Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Privia Health (PRVA) Capital Expenditures (2020 - 2023)

Privia Health has reported Capital Expenditures over the past 4 years, most recently at $23000.0 for Q4 2023.

  • For Q4 2023, Capital Expenditures rose 53.33% year-over-year to $23000.0; the TTM value through Dec 2023 reached $113000.0, up 8.65%, while the annual FY2023 figure was $113000.0, 8.65% up from the prior year.
  • Capital Expenditures for Q4 2023 was $23000.0 at Privia Health, up from $18000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $366000.0 in Q2 2020 and troughed at $1000.0 in Q3 2020.
  • A 4-year average of $88000.0 and a median of $34000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: soared 19600.0% in 2021 and later plummeted 91.88% in 2022.
  • Year by year, Capital Expenditures stood at $1000.0 in 2020, then skyrocketed by 15000.0% to $151000.0 in 2021, then crashed by 90.07% to $15000.0 in 2022, then surged by 53.33% to $23000.0 in 2023.
  • Business Quant data shows Capital Expenditures for PRVA at $23000.0 in Q4 2023, $18000.0 in Q3 2023, and $72000.0 in Q2 2023.